The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer

International Braz J Urol

Volumn 37, Issue 3, 2011, Pages 302-306

  Drivalos, Alexandros ^a   Papatsoris, Athanasios G ^a   Chrisofos, Michael ^a   Efstathiou, Eleni ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cadherins; Integrins; Prostate cancer; Review

Indexed keywords

CADHERIN; INTEGRIN; TUMOR PROTEIN;

DRUG ANTAGONISM; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REVIEW;

CADHERINS; HUMANS; INTEGRINS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 80051901366     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382011000300002     Document Type: Review

References (24)

1. Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C: Precursor lesions of prostate cancer. Crit Rev Clin Lab Sci. 2007; 44: 243-70.
2. Ramsay AG, Marshall JF, Hart IR: Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007; 26: 567-78.
3. Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006; 20: 3199-214.
4. Schmelz M, Cress AE, Scott KM, Bürger F, Cui H, Sallam K, et al.: Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia. 2002; 4: 243-54.
5. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Manolis C, et al.: The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One. 2008; 3:e3535.
6. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, et al.: Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst. 2007; 99: 868-80.
7. Trikha M, Cai Y, Grignon D, Honn KV: Identification of a novel truncated alphaIIb integrin. Cancer Res. 1998; 58: 4771-5.
8. Perlino E, Lovecchio M, Vacca RA, Fornaro M, Moro L, Ditonno P: Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am J Pathol. 2000; 157: 1727-34.
9. Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, et al.: beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res. 2005; 65: 6692-700.
10. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR: Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999; 59: 1655-64.
11. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR: Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol. 2003; 161: 817-26.
12. Wang J, Krill D, Torbenson M, Wang Q, Bisceglia M, Stoner J, et al.: Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res. 2000; 28: 308-15.
13. Pontes J Jr, Srougi M, Borra PM, Dall' Oglio MF, Ribeiro-Filho LA, Leite KR: E-cadherin and betacatenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol. 2010; 18: 179-84.
14. van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, et al.: The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gammacatenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate. 2007; 67: 1432-8.
15. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M: Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997; 57: 3189-93.
16. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Kosma VM: Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer. 1999; 80: 477-82.
17. Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P, et al.: The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol. 2010; 28: 534-40.
18. Walker MM, Ellis SM, Auza MJ, Patel A, Clark P: The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer. Mod Pathol. 2008; 21: 85-95.
19. Arenas MI, Romo E, Royuela M, Fraile B, Paniagua R: E-, N- and P-cadherin, and alpha-, betaand gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J. 2000; 32: 659-67.
20. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Smith DC, Small E, et al.: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2010; 25. [Epub ahead of print]
21. Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z, Foster B: A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs. 2010; 11.[Epub ahead of print]
22. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, wt al.: Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 2007; 67: 6925-35.
23. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, et al.: Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010; 221: 68-76.
24. Li H, Price DK, Figg WD: ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007; 18: 563-8.